Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationTransplantation, HomologousTransplantation, AutologousGraft vs Host DiseaseStem Cell TransplantationTransplantation ConditioningBone Marrow TransplantationHematopoietic Stem CellsHematologic NeoplasmsHematopoietic Stem Cell MobilizationStem CellsTreatment OutcomeTissue DonorsTransplantation ChimeraGraft SurvivalGranulocyte Colony-Stimulating FactorImmunosuppressive AgentsBusulfanLeukapheresisAntigens, CD34Myeloablative AgonistsRecurrenceCombined Modality TherapyMelphalanMultiple MyelomaCord Blood Stem Cell TransplantationRemission InductionHistocompatibility TestingGraft vs Leukemia EffectBlood Component RemovalVidarabineCyclophosphamideRetrospective StudiesHistocompatibilityCytomegalovirus InfectionsWhole-Body IrradiationLeukemiaAntineoplastic Combined Chemotherapy ProtocolsLiver TransplantationGraft vs Tumor EffectLeukemia, Myeloid, AcuteSalvage TherapyDisease-Free SurvivalKidney TransplantationSurvival RateTime FactorsSurvival AnalysisLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte TransfusionLymphocyte DepletionSiblingsMyelodysplastic SyndromesLymphoma, Non-HodgkinHematopoiesisPrecursor Cell Lymphoblastic Leukemia-LymphomaAnemia, AplasticHematologic DiseasesAntilymphocyte SerumNeoplasm, ResidualAdult Stem CellsMesenchymal Stem Cell TransplantationT-LymphocytesCytomegalovirusImmunocompromised HostEmbryonic Stem CellsTransplantationEtoposideFollow-Up StudiesTransplantation ImmunologyAcute DiseaseOpportunistic InfectionsBlood CellsInfectionChimerismFlow CytometryBone Marrow CellsTransplantation, IsogeneicCytarabineHLA AntigensVirus ActivationHodgkin DiseaseHepatic Veno-Occlusive DiseaseImmunosuppressionCell DifferentiationCell TransplantationBlood Cell CountMinor Histocompatibility AntigensHeart TransplantationCyclosporineBone MarrowBlood DonorsGraft RejectionPrognosisFatal OutcomeStem Cell NichePluripotent Stem CellsAntineoplastic Agents, AlkylatingLeukocyte TransfusionThiotepa